Cerebral Artery Syndrome Treatment Market Players:
- Bristol Myers Squibb
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Athersys, Inc.
- Janssen Pharmaceuticals, Inc
- Royal Philips
- AstraZeneca plc
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of cerebral artery syndrome treatment is estimated at USD 2.37 billion.
The global cerebral artery syndrome treatment market size crossed USD 2.24 billion in 2025 and is likely to register a CAGR of over 6.3%, exceeding USD 4.13 billion revenue by 2035.
North America is set to account for the largest revenue share of 35% by 2035, driven by rising awareness of minimally invasive stroke treatments and increasing prevalence of atrial fibrillation.
Key players in the market include Bristol Myers Squibb, Athersys, Inc., Janssen Pharmaceuticals, Inc, Royal Philips, AstraZeneca plc, Daiichi Sankyo Company, Limited, LIFESCAPES Inc, Shionogi & Co., Ltd., Fujitsu, Takeda Pharmaceutical Co Ltd.
